Skip to main content
Altuviiio logo

Patient Experiences - Courtney


“Keeping my factor levels high is important to me.”   
 

Controlling the bleeding 

Before ALTUVIIIO, I kept having breakthrough bleeding, and I had to infuse multiple times a week. I wanted a medication that would remain active for longer and help control my bleeding. I didn’t want to infuse so often.     
 

Making the switch 

I’ve always been upfront with my healthcare team about the severity or frequency of my bleeds. So, when it came to discussing switching to ALTUVIIIO, they were so supportive and recommended it for me.     
 

A positive impact 

ALTUVIIIO has exceeded my expectations. I only have to infuse once a week. And I no longer have the kind of breakthrough bleeding I used to have. Keeping my factor levels high is important to me.   
 

Get patients’ opinions 

If there’s one thing I’d tell doctors, it’s to ask patients their opinion on their current medication. Based on their response, you’ll know if it's time to have a conversation about switching.

This testimonial reflects one patient’s experience and has not been clinically evaluated. It is not intended to imply typical outcomes or substitute for clinical evidence. Courtney is a promotional speaker compensated by Sanofi.

Discover More Patient Experiences

Indication

ALTUVIIIO® is indicated for use in adults and pediatric patients with hemophilia A (congenital factor VIII deficiency) for:

  • Routine prophylaxis to reduce the frequency of bleeding episodes
  • On-demand treatment and control of bleeding episodes
  • Perioperative management of bleeding
Limitation of Use

ALTUVIIIO is not indicated for the treatment of von Willebrand disease.

Important Safety Information

Contraindications

ALTUVIIIO is contraindicated in patients who have had severe hypersensitivity reactions, including anaphylaxis, to the product or its excipients.

Warnings and Precautions
  • Allergic-type hypersensitivity reactions, including anaphylaxis, have occurred with ALTUVIIIO. Discontinue use of ALTUVIIIO if hypersensitivity reaction occurs and manage symptoms as appropriate.
  • Formation of neutralizing antibodies (inhibitors) to Factor VIII has been reported following administration of ALTUVIIIO. Monitor all patients for the development of Factor VIII inhibitors by appropriate clinical observations and laboratory tests.
  • If assessment of plasma Factor VIII activity is needed, it is recommended to use a validated one-stage clotting assay. The ALTUVIIIO Factor VIII activity level is overestimated by the chromogenic assay and a specific ellagic acid-based aPTT reagent in one-stage clotting assay by approximately 2.5-fold. If these assays are used, divide the result by 2.5 to approximate the patient's ALTUVIIIO Factor VIII activity level.
Adverse Reactions

The most common adverse reactions (>10% of subjects) reported in clinical trials were headache and arthralgia.

Indication

Important Safety Information

© 2026 Sanofi. All rights reserved. All trademarks mentioned are the property of the Sanofi group. MAT-US-2508205-v3.0-08/2026 Last Updated: August 2026